LIV Emles at Home ETF

Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today, the new FDA guidelines for early phases of drug development are expected to make it easier for Samaritan to manufacture small quantities of compounds for Phase I trials. The FDA's new guidance is intended to streamline drug development by facilitating short-term human studies, using sub-therapeutic doses to reveal mechanisms of action, pharmacokinetic, and the pharmacodynamic properties of a drug that will help Samaritan to select the most promising drugs to develop out of a family of drugs. Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We see these new less restrictive guidelines as most beneficial to small baby Biotechs with limited resources so we welcome these guidelines. The FDA estimates that work done to prepare a request to allow human testing of an experimental drug, currently costs $500,000 to $1 million, and Biotechs can test thousands of drugs only to bring a few to human trials." Dr. Greeson went on to say, "We believe Samaritan has an incredibly hot pipeline, and although early stage, we have found each of our indications has at least one promising drug that could bring incredible rewards to our shareholders." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan Pharmaceuticals is a drug development company driven to discover, develop, and commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan, in collaboration with Georgetown University, is advancing eight promising compounds, out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.